Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen- independent prostatic carcinoma

Urology

Volumn 50, Issue 1, 1997, Pages 100-105

  Ghossein, Ronald A ^a   Rosai, Juan ^b   Scher, Howard I ^b   Seiden, Michael ^b   Zhang, Zuo Feng ^b   Sun, Ming ^b   Chang, Gloria ^b   Berlane, Karen ^b   Krithivas, Krishna ^b   Kantoff, Philip W ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SURVIVAL RATE; TESTOSTERONE;

EID: 17444434615     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00127-1     Document Type: Article

References (26)

1. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, De Wolf W, et al: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 12: 2634-2639, 1994.
2. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, and Rosai J: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13: 1195-1200, 1995.
3. Katz AE, De Vries GM, Begg MD, Raffo AJ, Cama C, O'Toole K, Buttyan R, Benson MC, and Olsson CA: Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 75: 1642-1648, 1995.
4. Moreno JG, Croce CM, Fischer R, Monne M, Vikho P, Mulholland SG, and Gomella LG: Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52: 6110-6112, 1992.
5. Kunter U, Buer J, Probst M, Duensing S, Dallman I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A, et al: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 88: 590-594, 1996.
6. Gribben JG, and Nadler LM: Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction, in DeVita VT, Hellman S, and Rosenberg SA (Eds): Important Advances in Oncology 1994. Philadelphia, JB Lippincott, 1994, pp 117-129.
7. Scher HI, Mazumdar M, and Kelly WK: Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 88: 1623-1634, 1996.
8. Ben-Ezra J, Johnson DA, Rossi J, Cook N, and Wu A: Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. J Histochem Cytochem 39: 351-354, 1991.
9. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
10. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, and Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39, 1977.
11. SAS Institute Inc. SAS/STAT User Guide. Version 6. Cary, NC, SAS Institute Inc., 1990.
12. Cox DR: Regression models and life tables. J R Stat Soc Ser B 34: 187-220, 1972.
13. Cox DR: Partial likelihood. Biometrika 62: 269-279, 1975.
14. Israeli RS, Miller HM, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, De Blasio A, Edwards ET, Wise GJ, et al: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54: 6306-6310, 1994.
15. Cave H, Guidal P, Rohrlich P, Delfau MH, Broyart A, and Lescoeur B: Prospective monitoring and quantitation of residual blasts in childhood acute leukemias by polymerase chain reaction of delta and gamma T-cell receptor genes. Blood 83: 1892-1902, 1994.
16. Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M, Silver SM, and Ginsburg D: Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 79: 276-282, 1992.
17. Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, and Tindall DJ: In situ hybridization of prostatic-specific antigen mRNA in human prostate. J Urol 144: 1550-1556, 1990.
18. Warembourg M, Tranchant O, Atger M, and Milgrom E: Uteroglobin messenger ribonucleic acid: localization in rabbit uterus and lung by in situ hybridization. Endocrinology 119: 1632-1640, 1986.
19. Petros JA, and Andriole GL: Serum PSA after antiandrogen therapy. Urol Clin North Am 20: 749-756, 1993.
20. Campana D, and Pui CH: Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood 85: 1416-1434, 1995.
21. Bartram CR: Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. Clin Chim Acta 217: 75-83, 1993.
22. Potter MN, Cross NC, Van Dongen JJM, Saglio G, Oakhill A, Bartram CR, and Goldman JM: Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. Leukemia 7: 1302-1314, 1993.
23. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu GM, Ferrant A, Michaux JL, and Martial P: Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 82: 1618, 1993.
24. Brisco MJ, Condon J, Hughes E, Neoh S-H, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, et al: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343: 196-200, 1994.
25. Gilliland G, Perrin S, and Bunn FH: Competitive PCR for quantitation of mRNA, in Innis MA, Gelfand DH, Sninsky JJ, and White TJ (Eds): PCR Protocols. San Diego: Academic Press, 1990, pp 60-69.
26. Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitmore WF, Vugrin D, Scher HI, Nisselbaum J, and Golbey RB: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403-3407, 1983.